Strong revenue growth masked by profitability miss; M&A on track
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Maintained FY27 guidance but not raised despite 43% Q1 growth, suggesting prior guide was conservative or macro headwinds emerging.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 delivered a profitability miss (PAT -₹9.6 Cr vs path to positive) despite 43% revenue growth, with cyber-fraud masking execution challenges. FY27 guidance (₹1,065 Cr revenue, ₹172 Cr EBITDA) remains on track but management declined to revise upward despite claimed momentum, signaling caution. SessionM integration and Kognitiv AI-migration execution are key near-term risks.
₹256.6 Cr
Revenue · +43% YoY₹-9.6 Cr
Reported PAT · +null% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
43% revenue growth and strong execution
OVERSTATEDReported 43% includes SessionM (2m), Kognitiv; organic growth 17% YoY
EBITDA margin expansion from 11% to 17%
METQ1 EBITDA ₹44 Cr at 17% (₹256 Cr base); normalized after cyber fraud
PAT at ₹25 Cr normalized (cyber-fraud adjusted)
MISSActual PAT -₹9.6 Cr; cyber-fraud ₹9.5 Cr deferred tax adjustment
SessionM already profitable, generating cash
Partial2 months of integration; claimed INR 5-6 Cr free cash; server costs 50% revenue
111% NRR on core platform
MET111% reported; 116% excl large healthcare customer; churn ~5%
Earnings quality
What changed since the last call
Organic growth deceleration
DowngradeOrganic YoY 17% in Q1 vs prior 20-23% full year target; large healthcare customer stalling is headwind
Profitability trajectory
DowngradeQ1 PAT -₹9.6 Cr (normalized ₹25 Cr) vs prior guidance path to profitability; cyber-fraud masks integration margin pressure
SessionM acquisition structure
New₹17 Cr net cost (revised down from $20M enterprise value) for $32M ARR; profitability trajectory detailed (15% margin in 1 year, 35-40% in 2 years)
M&A guidance
MaintainedFY27 ₹1,065 Cr revenue (vs ₹1,000-1,050 Cr prior) maintained; will beat but no formal revision despite 43% Q1
AI product (aiRA) commercialization
New$2-2.5M ARR, 26 customers live, <10 paying; targeting 5-10% of revenue FY27; high-margin (80%+) but early adoption cycle
The Q&A
Analysts pressed hard on organic growth deceleration, customer concentration risk, SessionM execution, and why guidance wasn't raised. Management held firm on maintained guidance, acknowledged concentration but highlighted 75% new ACV growth, and detailed Kognitiv AI-upgrade path. CFO specific on metrics (NRR, ACV definitions); tone confident but cautious on upside.
SessionM migration timeline — Vinay Menon, ICICI Direct
AnsweredMigrations start end of year, early next year (3-4 fast-track of 45 customers). No upgrade revenue uplift; margins improve via infrastructure optimization and 10-15% NRR on $32M book.
Kognitiv upgrade execution — Shaurya Yadav, Kotak
AnsweredAccelerate next 10 in 2-3 quarters via AI platform. Prior migrations took 3-5 years; targeting 18-24 months. Margin accretion ₹10-15 Cr EBITDA expected from ₹75 Cr Kognitiv base.
NRR bifurcation — Shaurya Yadav, Kotak
Answered4-5% inflation/overages; ~10% upsells + new cohorts; ~5% churn. Organic gross margin 75%+ supports NRR expansion.
Cyber-fraud insurance recovery — Jayesh Sagar, Morgan Stanley
PartialPolicy in place; insurance provider working on claim. No customer/employee data breach; banking account compromise only. Recovery timeline unclear.
M&A multiples and discipline — Rishi Jhunjhunwala, IIFL
AnsweredPaying 0.3-0.5x revenue. ~90 companies in USD10-100M bracket available. Buying customer contracts at scale, not functionality.
Organic vs inorganic split — Rishi Jhunjhunwala, IIFL
Answered17% organic YoY; 6% currency tailwind. FY27 full-year organic expected 17-23% (including 6% currency). Large healthcare customer drag impacting Q1.
Agency-to-SaaS transition model — Akshay Jogani, Goldman Sachs
AnsweredTwo-step margin expansion: (1) shift backend work to India center, (2) full software automation. Brierley example: 200 people → 12 for same revenue. SessionM different (already SaaS); server costs 50% revenue (vs Capillary 7-10%); optimization alone is margin lever.
NRR, ACV definitions and Kognitiv treatment — Akshay Jogani, Goldman Sachs
AnsweredNo new ACV (no new contract signature). NRR flow counted next year, not this year (like-for-like basis). Only new contract wins count in new ACV.
Agentic commerce and loyalty relevance — Srinivasu, UBS
AnsweredAgents are rational; 1% difference matters vs human subconscious 2-3% acceptance. Loyalty becomes more promotion/precision critical. Capillary's <100ms turnaround and platform depth matter more. Agencies (competitors) have legacy tech.
Competitive positioning vs agencies — Shankar Narayanan, Nomura
AnsweredAgencies (Epsilon ₹2B, Merkle ₹500M+, others ₹100s M) dominate. Software <10% of revenues (Capillary, Salesforce, Oracle legacy). Shift from agencies to software driven by speed needs (2-month cycles unacceptable for CMOs).
Enterprise organic wins — Chintan Shah, Axis
AnsweredSome Fortune 50/500 organic wins (healthcare, pharmacy, fuel retail). 5-year presence in US; analyst rankings help. Stickiness real; M&A + organic combo strategy for super-large customers.
aiRA commercialization and economics — Sanjay Kumar Elangovan, Investec
PartialNo cannibalization (Engage only 5% of revenue). aiRA margins 80%+. Early cohort adoption good; budgeting cycles for large enterprise constraining; targeting 5-10% of revenue FY27.
FY27 guidance revision — Kumar Saurabh, Goldman Sachs
DodgedWill definitely beat guidance but won't revise now. Let results play out. Maintaining discipline on guidance.
Guidance
FY27 ₹1,065 Cr (vs prior ₹1,000-1,050 Cr)
MediumManagement confident 'will definitely beat' but not revising formally. Includes SessionM ₹32M ARR + organic 17-23% growth.
FY27 EBITDA ₹172 Cr (~16% margin at ₹1,065 Cr revenue)
MediumOrganic EBITDA claimed 20%+; consolidated dilution from SessionM integration (break-even now, ramp to 15% in 1yr, 35-40% in 2yr)
Risks the call surfaced
Customer concentration
HighOne large healthcare customer drives 116% NRR if excluded vs 111% with. Concentration risk on loyalty business stickiness.
Cyber-fraud impact
Medium₹9.5 Cr banking fraud at subsidiary; no customer data breach. Insurance claim in progress; recovery timing unclear.
SessionM integration execution
Medium₹17 Cr acquisition claimed break-even in 2 months; server cost 50% revenue (vs Capillary 7-10%). Margin ramp from break-even to 15% (1yr) to 35-40% (2yr) execution dependent.
Kognitiv migration execution
MediumFirst Kognitiv customer migration Sep 1 using AI platform; 16-17 customers total; target 18-24 month cycle (vs prior 3-5 years). Margin accretion ₹10-15 Cr EBITDA from ₹75 Cr base.
Organic growth deceleration
MediumQ1 organic growth 17% YoY vs prior 20-23% guidance. Large healthcare customer stalling; inflation/overages only 4-5% of 111% NRR.
aiRA adoption timing
LowaiRA $2.5M ARR with 26 customers live, <10 paying. Target 5-10% of revenue (₹13-25 Cr at ₹1,065 revenue) is ambitious. Large enterprise budgeting cycles constraining.
Management
Score 7/10. Precise on metrics (NRR, ACV, ARR definitions); candid on customer concentration, fraud, integration challenges. Deflects on FY27 guidance revision despite 43% Q1. Track record: acquired 3 pre-2020 companies (Brierley, Persuade, Rewards+) to >20% EBITDA; Kognitiv first migration Sep 1 on schedule; SessionM $32M ARR fully signed. Mixed on organic growth (17% vs 20-23% guidance).
1 · Sep 2026
First Kognitiv customer migration on Capillary platform; AI-based upgrade proof of concept
2 · Sep 2026 – Sep 2027
SessionM integration; server cost reduction (target 5-10% margin pre-upgrade)
3 · H2 FY27
SessionM customer upgrades begin; aiRA adoption ramp (targeting 5-10% revenue)
SessionM integration and Kognitiv AI-migration execution are key near-term risks.
Growth intact, profit stumbled: why Capillary's FY27 guidance remains cautious
Revenue jumped 43% to ₹256.6 crore, but reported profit fell ₹9.6 crore into the red. A cyber-fraud loss accounts for ₹9.5 crore, but integration costs obscure the deeper story — and why management declined to raise guidance despite the strong quarter.
₹256.6 Cr
+43% YoY
-₹9.6 Cr
cyber-fraud ₹9.5 Cr embedded
₹44 Cr
17% margin; claimed organic 20%+
17%
vs prior 20–23% guidance
111%
116% excl one healthcare customer
The headline looks strong: ₹256.6 crore revenue, up 43% year-on-year, is exactly what a founder wants to print. But reported profit came in at -₹9.6 crore. A ₹9.5 crore cyber-fraud loss (banking account compromise, no customer data breach) explains much of it, but the call reveals a deeper tension: management declined to revise FY27 guidance upward despite the strong quarter, citing integration headwinds and wanting to "let results play out." That caution is the real story.
Where the profit came from — and what's missing
EBITDA paints a different picture: ₹44 crore at 17% margin, up from 11% year-ago. Management claims organic EBITDA margins exceed 20%, suggesting SessionM and Kognitiv acquisitions are temporarily diluting consolidated margins while integrating. That's the M&A playbook — buy at lower margins, migrate to platform, lever margins later. But it also means near-term profit is under pressure, and the cyber-fraud loss surfaced this tension at an awkward moment.
Management's claims, graded
43% revenue growth and strong execution
OverstatedReported 43% includes SessionM (2m), Kognitiv; organic growth 17% YoY
EBITDA margin expansion from 11% to 17%
SupportedQ1 EBITDA ₹44 Cr at 17%; organic claimed >20%
PAT normalized at ₹25 Cr
ContradictedReported PAT -₹9.6 Cr; normalization bridge not reconciled
SessionM profitable, generating ₹5–6 Cr free cash
Partial2 months only; server costs 50% revenue (vs Capillary 7–10%); margin ramp untested
111% NRR on core platform
Supported111% reported; 116% excl large healthcare customer; churn ~5%
What shifted on this call
SessionM deal finalized: ₹17 crore net for $32M ARR; fully migrated on Capillary contracts. Management targets 15% EBITDA in 1 year, 35–40% in 2 years via server-cost optimization.
Organic growth reset downward: Q1 organic 17% YoY vs prior full-year 20–23% guidance. Large healthcare customer stalling is the culprit; management acknowledged concentration but framed it as minority risk.
Kognitiv AI-based migration accelerated: First customer migrating Sep 1 on Capillary's AI platform (vs legacy 3–5 year cycles). Target is 18–24 months for all 16–17 customers; EBITDA accretion ₹10–15 crore from ~₹75 crore base revenue.
FY27 guidance maintained, not raised: Revenue target raised modestly from ₹1,000–1,050 Cr to ₹1,065 Cr (+1.4% midpoint); EBITDA to ₹172 Cr (~16% consolidated margin). Despite 43% Q1 growth, management said "we will definitely beat this but won't revise formally" — a cautious stance that signals either macro softness or execution confidence gaps.
How the street is positioned
Price action holds but consolidates. Post-result, the stock popped +7.74% on day 1 (₹534.95 to ~₹576), but by day 3 had eased to +4.79% (current ₹560.55). This is not a fade-to-red but a healthy consolidation — the market sees headline growth as real, cyber-fraud as isolated, but caution on execution as justified.
Valuation sits at inflection. Stock trades at ₹560.55, down 29.84% from all-time high (₹798.95) but up 20.73% from 52-week low (₹464.3). It's above 20-day SMA (₹510.95) and 50-day SMA (₹507.73), signalling uptrend recovery. RSI at 65.1 is neutral; volume increasing. At this level, the pullback from ATH looks like a repricing for execution risk, not panic.
Ownership shifts reveal caution. FII ownership down 9 bps to 3.34% (trimming); DII up 78 bps to 19.38% (adding). Promoter down 78 bps to 51.45%. The FII trim is mild but telling: overseas investors took profit on the +7.74% pop rather than adding at strength. Domestic institutions (DII) are the net buyers. No significant insider/promoter selling flagged.
The bull-bear ledger
Organic gross margin 75%+ sustained; NRR 111% with only 5% churn = best-in-class stickiness
New ACV 75% YoY growth; 465 brands, 25 Fortune 500 customers = customer diversification accelerating
SessionM $32M ARR fully signed, zero churn on acquisition = plug-and-play SaaS asset with proven demand
Kognitiv first migration Sep 1 on Capillary's AI platform; ₹10–15 Cr EBITDA accretion = scale unlocks margin
Analyst ranking: Forrester Wave #1 in SaaS loyalty = moat via credibility and inbound momentum
Customer concentration: one large healthcare customer drives 116% NRR if excluded vs 111% with = ~5% of NRR at risk
Organic growth deceleration: 17% Q1 YoY vs prior 20–23% = core momentum loss unexplained
Reported PAT negative despite 43% growth; integration costs + cyber-fraud mask true profitability pressure
SessionM margin ramp from 50% server costs to 35–40% EBITDA in 2 years = execution risk on novel cost structure
Guidance non-revision despite momentum = management confidence gap or hidden headwinds
aiRA adoption slow: $2.5M ARR with <10 paying customers vs 5–10% FY27 target = timing/scale risk
Risks, ranked by holder concern
Customer concentration on one large healthcare customer
HighStall in this customer dragged organic growth from 20–23% to 17%. Loss would spike churn and reduce NRR from 111% to 116%. Concentration risk is material to stickiness narrative.
Organic growth deceleration persists
High17% Q1 YoY is 300–600 bps below prior guidance. If this is the new baseline, FY27 organic target (17–23%) compresses and all upside estimates shrink. Core business momentum is the denominator.
Profitability trajectory under pressure
HighReported PAT negative despite 43% growth. Normalized PAT bridge opaque. If SessionM/Kognitiv integration margins remain dilutive, path to ₹172 Cr EBITDA (implied ₹100+ Cr PAT) stalls.
SessionM server-cost optimization untested at scale
Medium50% server costs is architectural debt. Optimizing 45 customers and $32M ARR is the test. Margin trajectory from break-even to 15% (1yr) to 35–40% (2yr) is execution-dependent.
Kognitiv AI-based migration execution risk
MediumFirst customer Sep 1 is proof point. Scaling 16–17 customers in 18–24 months (vs legacy 3–5 years) is novel. Delays push ₹10–15 Cr EBITDA accretion into H2 or FY28.
aiRA adoption slower than modeled
Low$2.5M ARR with <10 customers paying. 5–10% of FY27 revenue (₹13–25 Cr target) requires 5–10x growth. Enterprise budgeting cycles are the constraint, not product fit.
The debate
What to watch next
1 · Organic growth re-acceleration (next 2 quarters)
Does organic growth move back toward 20%+ baseline, or is 17% the new run-rate? The large healthcare customer stall is the near-term headwind. If it stabilizes or customer diversification accelerates, organic inflects back. If not, FY27 guidance is at risk.
2 · Kognitiv first customer migration traction (Sep 2026)
Does the first customer migration on Capillary's AI platform succeed? Customer satisfaction, timeline adherence, and feature completeness are the watch-outs. Success validates the 18–24 month cycle case; delay kills it.
3 · SessionM margin ramp and profitability visibility (Q2/Q3)
Does server-cost optimization materialize? Management must show SessionM EBITDA trending toward 15%+ by Q3 for the margin accretion case to hold. Stall at break-even resets valuation lower.
Capillary is a steady execution story, not a step-change. The M&A playbook is proven (Brierley, Persuade, Rewards+ all >20% EBITDA post-migration), and SessionM + Kognitiv are the next tests. But Q1's profit miss and organic deceleration are real cautions — integration headwinds and macro softness are material near-term. The 30% pullback from ATH is warranted; it's not panic but not bargain either.
Track organic growth as the denominator for all upside. If 17% is durable, all forward estimates compress. SessionM margin progression is secondary but confidence-building: proof points on server-cost wins unlock the larger M&A strategy. Kognitiv Sep 1 migration is the inflection; success on this customer resets the risk/reward higher.
A Hold at ₹560 is fair. Upside exists (M&A execution, Kognitiv proof point, organic recovery, analyst rankings driving inbound). So do risks (concentration, organic decel, profitability pressure). The next two quarters settle whether this is a temporary stall or a structural deceleration.
Capillary posts consolidated net loss of ₹9.6 Cr on one-off ₹33.4 Cr fraud charge
revenue +42.7% · margins compressing
₹256.64 Cr
+42.7% YoY
₹-9.55 Cr
-3.64%
₹-1.2
Capillary Technologies' consolidated Q1 FY27 (quarter ended 30 June 2026) revenue rose 42.7% YoY and 34.1% QoQ to ₹256.64 Cr, lifted by SessionM's consolidation from 1 May 2026 alongside organic growth. Yet the group reported a consolidated net LOSS of ₹9.55 Cr, reversing a ₹43.36 Cr profit in Q4 FY26 and a marginal ₹0.75 Cr profit a year ago. The swing was driven entirely by a ₹33.39 Cr (€3.04 million) exceptional expense — a cyber-enabled banking fraud at SessionM Czech Republic s.r.o, the Czech step-down subsidiary acquired with SessionM, which saw unauthorised bank transfers during the quarter. Strip that out and pre-tax operating profit (before exceptional items) was ₹24.80 Cr, up 41.6% QoQ from ₹17.52 Cr and up sharply from a near-breakeven ₹0.55 Cr a year ago — underlying profitability improved even as the headline print shows red.
Q1 FY-2027 vs prior quarters
No year-ago quarter on record — YoY cells may be blank.
Adjusted net margin still compressed, to roughly 9.3% from ~21.9% in Q4 FY26 (per prior record), as employee costs jumped to ₹119.84 Cr (+33.8% QoQ) on SessionM integration and, per management's own pre-results commentary, routine annual salary increments; professional/consultancy and software & server costs also rose with the wider group perimeter. This tracks the prior guidance that FY27 margins would see near-term dilution from acquisition integration even as absolute EBITDA grows: profit before D&A/finance/exceptional items (₹46.01 Cr) rose 20.7% QoQ — absolute profitability up, percentage margin down, exactly the pattern flagged on the May 2026 concall. Management's claim that core (non-acquired) business margins continue to expand cannot be independently verified from the filing's single-segment P&L.
The stock went into the print at ₹532.35, up 3% over the past month of trading.
What the summary numbers don't show
Forensic audit initiated (31 Jul 2026) into the banking fraud — ~₹4.67 Cr of diverted funds already frozen by banking authorities as recovery/insurance claims proceed.
Management projects strong revenue growth for FY27, expecting to cross the INR 1,000-1,050 crore mark, primarily driven by the recent SessionM acquisition and continued organic momentum. While absolute EBITDA is expected to grow, percentage margins may experience near-term dilution due to acquisition integration, but t
— This quarter: met
On an annualised run-rate basis, the quarter's ₹256.64 Cr revenue tracks to roughly ₹1,026 Cr for FY27 — squarely inside management's guided ₹1,000-1,050 Cr band, so revenue guidance is on track. No formal Street consensus for this specific quarter was found in a web search; commentary on FY27 broadly expects 15-20% full-year PAT growth, a bar the fraud-hit reported number doesn't address but the ex-exceptional print is tracking toward. Standalone (the India entity alone, insulated from the Czech subsidiary loss) stayed solidly profitable at ₹7.77 Cr PAT — down from ₹9.90 Cr in Q4 FY26 but a turnaround from a ₹5.12 Cr loss a year ago — underscoring that the reported group loss is subsidiary-specific, not a standalone-business problem.
W1
Outcome of the forensic audit and insurance/banking-authority recovery process for the ₹33.39 Cr Czech fraud (₹4.67 Cr already frozen) — will determine if any of the loss reverses in coming quarters.
W2
FY27 revenue guidance of ₹1,000-1,050 Cr — Q1 annualised run-rate (~₹1,026 Cr) is on track; confirm SessionM integration sustains this pace into Q2.
W3
Margin trajectory toward management's steady-state EBITDA margin target of 25-30% — current adjusted EBITDA margin ~17.9% needs to show QoQ recovery as acquisition integration normalizes.